新型冠状病毒

BioNTech/Pfizer boosters show 95.6% efficacy against Covid

Results from first randomised, controlled trial suggest extra dose effective regardless of age, sex or race

A booster shot of the BioNTech/Pfizer vaccine is 95.6 per cent effective against Covid-19 compared with those receiving two shots and a placebo, the companies said on Thursday, citing preliminary results from the first randomised, controlled trial on boosters.

Ugur Sahin, the head of BioNTech, said the “important data” added to the body of evidence suggesting that a booster dose could help “protect a broad population of people from this virus and its variants”. 

He added: “Based on these findings we believe that, in addition to broad global access to vaccines for everyone, booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy.”

您已阅读29%(690字),剩余71%(1731字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×